Port-wine stain

A newborn has a sharply demarcated pink patch over the forehead. The lesion itself is usually diagnosed by inspection. The high-value decision is what sits behind it: brain risk follows the forehead phenotype, glaucoma risk follows periocular involvement, and an early normal MRI cannot close the case. [12][14][15]

Meet the patient

Use current ISSVA language: capillary malformation. PWB is a simple, slow-flow vascular malformation composed of ectatic superficial dermal capillary-sized vessels, especially post-capillary venules. It is present at birth, expands proportionally, and does not undergo the proliferative-then-involuting course of infantile haemangioma. [3][15]

[3] [15]

PWB affects roughly three in 1,000 newborns and occurs across sexes and skin tones. Apparent colour and laser response vary with epidermal melanin, but skin tone does not change the need to assess facial distribution and associated features. [3][9]

The lesion is usually sporadic. A postzygotic mosaic variant found in affected tissue explains why blood testing may be negative. Recurrence for siblings or future children is expected to be low, but counsel it as low rather than zero because mosaicism and genetic heterogeneity limit absolute promises. [5][6]

The distribution is the most important clinical feature, and the colour change over a lifetime is the strongest argument for early laser.[3]

Shirley and colleagues identified the activating mosaic GNAQ p.R183Q variant in most, but not all, sampled isolated PWBs and Sturge-Weber lesions. Subsequent work has described genetically heterogeneous capillary-malformation phenotypes, including GNA11-associated disease. The safe conclusion is “a common mosaic GNAQ driver,” not “every PWB has one mutation.” [4][5][6]

The landmark tissue study showed modest increased ERK activity, but it did not establish the long PLC-beta → IP3/DAG → calcium → vascular ectasia chain previously taught as settled fact. Reduced perivascular innervation is a proposed contributor, not a proven universal cause, and it should not be used to resurrect a trigeminal-dermatome model of facial distribution. [4][6][14]

Histology, when obtained, shows dilated superficial dermal capillary-sized vessels with otherwise mature endothelium and no haemangioma-like proliferative phase. PWB is usually diagnosed clinically; biopsy is reserved for diagnostic uncertainty or an atypical nodule rather than routine confirmation. [3][15]

Investigations — clinical, then screen the syndrome

At birth, PWB is a flat pink-red to violaceous patch with a geographic or segmental border. It may blanch partly or completely; blanching is not an absolute discriminator from naevus simplex. Over time it can darken, thicken, become nodular, and develop soft-tissue or bony overgrowth, but neither the timing nor the degree of progression is universal. [3][13][15]

For brain risk, the useful forehead territory is bounded inferiorly by a line from the outer canthus to the top of the ear and includes the upper eyelid. Larger, bilateral, or median forehead involvement increases concern, but a small lesion in that territory still deserves specialist assessment. Do not label cheek or jaw lesions as “V2/V3 therefore zero risk.” [12][14][15]

For ocular risk, record any involvement of the upper eyelid, lower eyelid, or periocular skin. Glaucoma may present in infancy or later, so a normal first examination does not end surveillance. Ask about photophobia, tearing, corneal clouding, or apparent eye enlargement, but do not wait for symptoms before referral. [12][15]

Adjuncts and alternatives

[3] [13] [15]

A large segmental facial infantile haemangioma, not a PWB, is the vascular lesion linked to PHACE syndrome. That distinction prevents both missed PHACE work-up and inappropriate propranolol counselling for a capillary malformation. [11]

A PWS is often the visible clue to a syndrome; the recurring failure is failing to screen. Two dominate the exams.[1][7]

A typical PWB needs no biopsy. If tissue is sampled because the diagnosis is uncertain or a nodule is atypical, expect ectatic thin-walled vessels in superficial dermis without the endothelial proliferation of infantile haemangioma. GLUT1 supports infantile haemangioma in the right context, but an extended immunohistochemical panel is not routine for a clinically classic PWB. [3][15]

Progressive nodularity reflects changing vessel calibre and surrounding soft tissue, but exact vessel depth and diameter ranges should not be quoted unless a primary histology source and method are specified. Rapid growth, ulceration, destructive change, or persistent diagnostic uncertainty warrants biopsy rather than a presumption of benign “cobblestoning.” [3][13]

Clinical and Bedside Assessment

First confirm morphology, then map risk. Document colour, border, blanching, thickness, nodules, mucosal involvement, lesion extent, midline crossing, and serial photographs. Palpate for warmth, thrill, or bruit; fast-flow signs move the case away from a simple capillary malformation. [3][15]

[7] [12] [15]

Investigations

A clinically typical isolated PWB needs no blood test, biopsy, or imaging to prove the skin diagnosis. Investigations answer a syndromic question and should be directed by phenotype and specialists. [3][15]

Neurology and neuroimaging

A newborn or infant with a high-risk forehead PWB should have baseline paediatric neurology assessment and periodic follow-up. Families need a seizure and developmental safety-net even when the infant is well. EEG may contribute to specialist assessment but is not diagnostic of Sturge-Weber syndrome by itself. [12]

Routine screening MRI is not universally recommended for every asymptomatic high-risk infant. Selective imaging is reasonable after specialist discussion, particularly with extensive or bilateral lesions, subtle symptoms, or when presymptomatic treatment is being considered. A normal early scan can be falsely reassuring and does not exclude later radiological SWS. [12]

If an asymptomatic screen is chosen, expert centres may use a fast, non-sedated MRI approach with susceptibility-sensitive sequences. Once seizures, focal deficits, developmental regression, or stroke-like episodes occur, obtain an optimized symptom-directed MRI protocol with appropriate pre- and post-contrast sequences. Do not substitute CT as routine screening merely to find calcification. [12]

Ophthalmology

Any upper- or lower-eyelid/periocular PWB warrants prompt paediatric ophthalmology assessment. Baseline examination includes intraocular pressure and a complete ocular examination. Follow-up is lifelong and individualized because glaucoma risk is not confined to infancy. [12][15]

Limb overgrowth or fast-flow signs

A limb capillary malformation with overgrowth or venous/lymphatic change belongs in a multidisciplinary vascular-anomalies service. Doppler ultrasound or MRI is selected to define the malformation and its complications. Warmth, pulsation, thrill, or bruit warrants targeted fast-flow imaging for Parkes Weber syndrome or another arteriovenous lesion. [7][15]

Management — Resuscitation

An uncomplicated PWB needs no resuscitation. Acute priorities arise from associated disease: treat a seizure using the local paediatric seizure pathway and seek urgent neurology input; urgent eye review is needed for corneal clouding, painful photophobia, or apparent globe enlargement; sudden painful limb swelling or dyspnoea in a patient with KTS requires thromboembolism assessment. [5][7][12]

Management — Topical and Physical Modalities

There is no routine topical drug that replaces laser. Timolol, sirolimus/rapamycin, imiquimod, and other anti-angiogenic adjuncts remain investigational for PWB; small or uncontrolled studies do not justify an infant-use protocol. [4][8]

Pulsed dye laser

PDL is first-line when the patient or family wants lightening. It uses selective photothermolysis of oxyhaemoglobin in ectatic vessels. Starting in infancy can improve access to thinner skin and may reduce visible-difference burden, but “earlier” is not a promise of complete clearance and does not justify a universal starting age. [13][15]

There is no scientifically established universal session interval or parameter set. The experienced laser surgeon selects and titrates wavelength, spot size, fluence, pulse duration, overlap, epidermal cooling, and endpoint according to location, depth, colour, phototype, prior response, and device. A test area may be appropriate. [13]

Set expectations before treatment: most patients need multiple sessions; meaningful lightening is common, complete clearance is uncommon, response varies by anatomy and phototype, and recurrence or re-darkening can require touch-ups. Do not quote a fixed “6–12 sessions,” “6–8-week interval,” or “70–90 per cent clearance” as a universal promise. [13]

Expected short-term effects include pain, oedema, and purpura or colour change. Dyspigmentation, blistering, textural change, and scarring are less common but material harms. Cooling, cautious overlap, and phototype-aware settings matter. For treatment within the orbital rim, use properly fitted corneo-scleral shields placed and monitored by a trained clinician; for treatment outside the orbital rim, use laser-wavelength-specific external eye shields. [9][13]

Analgesia and anaesthesia

Analgesia and movement control are individualized by age, lesion size and site, anticipated pain, eye safety, previous experience, child/family preference, and local expertise. Small or moderate lesions may be treated with cooling and topical/local techniques; general anaesthesia may be reasonable for extensive, painful, or safety-critical treatment but is not “standard for all infants.” If repeated general anaesthesia is proposed, use shared decision-making with a paediatric anaesthesia team. [13]

Refractory or hypertrophic disease

Longer-wavelength devices such as alexandrite or Nd:YAG can reach deeper hypertrophic or nodular vessels but carry greater non-target thermal injury and scarring risk. Reserve them for selected, PDL-resistant disease in expert centres. IPL, fractional devices, and photodynamic therapy have limited or geographically concentrated evidence and are not interchangeable with first-line PDL. [8][13]

Camouflage, visible-difference support, and the option of no active treatment are legitimate choices. Treatment is preference-sensitive: the goal is not to imply that a birthmark must be hidden, but to offer accurate options and support. [13]

Management — Procedural and Surgical

Focal debulking, contour surgery, mucosal reduction, or excision may help selected hypertrophic, nodular, bleeding, or function-limiting disease after multidisciplinary assessment. Surgery does not remove the underlying field of mosaic malformation, so recurrence and adjacent progression remain possible. [3][13]

A rapidly growing, ulcerated, unusually firm, or diagnostically uncertain nodule should be sampled before destructive treatment. Routine biopsy of stable nodularity is unnecessary. [3][15]

Management of Syndromic Associations

Sturge-Weber syndrome

SWS management is phenotype-led and multidisciplinary. Neurology individualizes seizure treatment and considers epilepsy surgery for selected drug-resistant disease; ophthalmology treats glaucoma medically and/or surgically according to age and mechanism; developmental, vision, physiotherapy, and educational support address functional effects. Presymptomatic aspirin or antiseizure medication remains promising but unproven and should not be prescribed as a universal prophylactic regimen. [5][12]

Glaucoma mechanisms vary with age and include anterior-chamber angle abnormalities in early-onset disease and elevated episcleral venous pressure. This is why one mechanism, one drug list, and one fixed follow-up interval are inadequate. [12]

Klippel-Trenaunay syndrome

KTS is a slow-flow capillary-lymphatic-venous malformation with limb overgrowth, usually within the PIK3CA-related overgrowth spectrum. Management is coordinated by a vascular-anomalies team and may include compression, skin and lymphatic care, orthopaedic planning, targeted venous intervention, and individualized thrombosis prevention in high-risk situations. [7]

Do not describe arteriovenous shunts as a routine KTS component. A warm limb with a thrill or bruit suggests Parkes Weber syndrome, a fast-flow capillary malformation-arteriovenous fistula phenotype requiring different imaging and intervention planning. [7][15]

Associated Syndromes

• Sturge-Weber syndrome: high-risk facial PWB with variable leptomeningeal and ocular vascular involvement; the complete historical triad is not required. [5][12]
• Klippel-Trenaunay syndrome: slow-flow capillary-lymphatic-venous malformation plus limb overgrowth, commonly PIK3CA mosaic. [7]
• Parkes Weber syndrome: fast-flow capillary stain with arteriovenous fistulae and overgrowth; warmth, thrill, or bruit are the bedside clues. [15]
• Phacomatosis pigmentovascularis: capillary malformation plus a pigmentary naevus; extracutaneous involvement varies and specialist assessment is phenotype-directed. [16]
• PHACE syndrome: large segmental infantile haemangioma with structural arterial/cardiac/eye associations, not a PWB syndrome. [11]

Complications and Pitfalls

[7] [12] [13]

The classic examination error is to say “V1 PWB mandates neonatal MRI.” Replace it with: “Forehead involvement predicts brain risk; any eyelid involvement predicts glaucoma; refer to neurology and ophthalmology; asymptomatic MRI is specialist-dependent and may be falsely negative early.” [12][14]

Prognosis and Disposition

PWB persists. Colour, thickness, nodularity, overgrowth, psychosocial effect, and laser response vary between patients. PDL can provide meaningful lightening, but complete clearance is uncommon and touch-ups may be needed. Early specialist discussion lets the family choose treatment without promising prevention of every later change. [3][13]

[7] [12] [15]

Special Populations

Infants and children

Infancy is a useful time for diagnosis, referral, photography, safety-netting, and laser discussion. Do not delay neurology or ophthalmology pathways while waiting for laser, and do not delay laser solely to complete routine MRI when imaging is not otherwise indicated. Analgesia and anaesthesia are individualized. [12][13]

Darker skin phototypes

Epidermal melanin narrows the therapeutic window for PDL and increases dyspigmentation risk. Use an experienced laser service, cautious phototype-aware settings, epidermal cooling, and realistic counselling; do not compensate by promising that “higher fluence” is routinely required. [9][13]

Pregnancy and adulthood

An uncomplicated PWB does not itself mandate pregnancy-specific treatment. For KTS or extensive venous disease, pregnancy planning should include vascular, obstetric, and thrombosis expertise. In adults, new atypical or rapidly changing nodules require diagnostic review; stable hypertrophy can be assessed for laser, contour, or surgical options according to goals. [7][13]

Follow-up and Monitoring

Avoid invented schedules. Dermatology follow-up follows the laser course and patient goals; neurology follows brain-risk phenotype and symptoms; ophthalmology determines lifelong glaucoma surveillance frequency; vascular-anomalies and orthopaedic services follow overgrowth and venous/lymphatic morbidity. [7][12][13]

Families should know what requires urgent review: a first seizure, persistent focal weakness, developmental regression, eye pain/photophobia/tearing/clouding, apparent eye enlargement, sudden limb swelling or dyspnoea, or a rapidly changing nodule. [7][12]

Evidence, Guidelines, and Regional Differences

The controlling evidence is a combination of the 2013 mosaic-GNAQ tissue study, the forehead vascular-territory cohort, and 2021 multidisciplinary consensus statements for PWB treatment and SWS neurology/neuroimaging/ophthalmology. These sources support referral and treatment principles but leave genuine uncertainty around presymptomatic therapy, optimal asymptomatic imaging, ideal laser interval, and comparative adjuncts. [6][12][13][14]

Current controversies

• Asymptomatic MRI: selective specialist-led imaging can identify some presymptomatic disease, but early sensitivity is limited and a negative scan can falsely reassure. [12]
• Presymptomatic aspirin or antiseizure medication: retrospective signals exist, but routine prophylaxis is not established. [5][12]
• Laser timing and interval: early treatment may help, but there is no universal starting age, interval, endpoint, or number of sessions. [13]
• Adjuncts and PDT: evidence remains heterogeneous; promising signals do not establish a standard protocol. [8][13]

The mantra, and the memory device

Ward-round test — three stems, thirty seconds each

Exam application bank (NEET-PG / INICET)

Worked stem 1 — the well infant with forehead and eyelid involvement

Say: “This is a congenital capillary malformation. The forehead creates an SWS brain-risk pathway, and the eyelid creates a glaucoma pathway. I will arrange paediatric neurology and ophthalmology assessment, explain seizure and eye safety-netting, and let specialists decide whether asymptomatic MRI is useful; a normal early MRI would not exclude SWS.” [12][14]

Worked stem 2 — the differential trap

A PWB is present at birth and persists. Naevus simplex commonly fades. Infantile haemangioma is a vascular tumour that proliferates in early weeks and then involutes, but a precursor may already be visible at birth. The answer is the full timeline and morphology, not the unsafe binary “visible at birth means never haemangioma.” [3][15]

Worked stem 3 — laser counselling

Say: “PDL is first-line if treatment is wanted. We individualize settings, endpoint, interval, analgesia, and anaesthesia; use cooling and strict eye protection; expect multiple sessions and variable lightening; complete clearance is uncommon and touch-ups may be needed.” [13]

Worked stem 4 — limb overgrowth

A slow-flow capillary-lymphatic-venous malformation with overgrowth suggests KTS. Warmth, thrill, or bruit suggests fast-flow Parkes Weber syndrome instead. Refer to a multidisciplinary vascular-anomalies service and choose imaging to answer the flow and extent question. [7][15]

References

1. [1]Higueros E, Roe E, Granell E, et al. Sturge-Weber Syndrome: A Review. Actas Dermosifiliogr, 2017.PMID 28126187
2. [3]Escobar K, Pandher K, Jahnke MN. Capillary Malformations. Dermatol Clin, 2022.PMID 36243429
3. [4]Sánchez-Espino LF, Ivars M, Antoñanzas J, et al. Sturge-Weber Syndrome: A Review of Pathophysiology, Genetics, Clinical Features, and Current Management Approache. Appl Clin Genet, 2023.PMID 37124240
4. [5]Yeom S, Comi AM. Updates on Sturge-Weber Syndrome. Stroke, 2022.PMID 36263782
5. [6]Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med, 2013.PMID 23656586
6. [7]John PR. Klippel-Trenaunay Syndrome. Tech Vasc Interv Radiol, 2019.PMID 31864529
7. [8]Wang B, Mei X, Wang Y. Adjuncts to pulsed dye laser for treatment of port wine stains: a literature review. J Cosmet Laser Ther, 2021.PMID 35422188
8. [9]Eckembrecher FJ, Eckembrecher DG, Camacho I. A review of treatment of port-wine stains with pulsed dye laser in fitzpatrick skin type IV-VI. Arch Dermatol Res, 2023.PMID 37253863
9. [11]Garzon MC, Epstein LG, Heyer GL, et al. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr, 2016.PMID 27659028
10. [12]Sabeti S, Ball KL, Bhattacharya SK, et al. Consensus Statement for the Management and Treatment of Sturge-Weber Syndrome: Neurology, Neuroimaging, and Ophthalmology Recommendations. Pediatr Neurol, 2021.PMID 34153815
11. [13]Sabeti S, Ball KL, Burkhart C, et al. Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome. JAMA Dermatol, 2021.PMID 33175124
12. [14]Waelchli R, Aylett SE, Robinson K, et al. New vascular classification of port-wine stains: improving prediction of Sturge-Weber risk. Br J Dermatol, 2014.PMID 24976116
13. [15]Poliner A, Fernandez Faith E, Blieden L, et al. Port-wine Birthmarks: Update on Diagnosis, Risk Assessment for Sturge-Weber Syndrome, and Management. Pediatr Rev, 2022.PMID 36045161
14. [16]Kumar A, Zastrow DB, Kravets EJ, et al. Extracutaneous manifestations in phacomatosis cesioflammea and cesiomarmorata: Case series and literature review. Am J Med Genet A, 2019.PMID 30920161